Valeant a Step Closer to Medicis - Analyst Blog
20 11월 2012 - 10:45PM
Zacks
Valeant Pharmaceuticals
International, Inc. (VRX) is a step closer to acquiring
Medicis Pharmaceutical Corp. (MRX) with the
US
Federal Trade Commission granting the early
termination of the waiting period under the Hart-Scott-Rodino
Antitrust Improvement Act of 1976.
Valeant Pharma had announced its intention to acquire specialty
pharmaceutical company, Medicis Pharma in September 2012. The
companies signed a definitive merger agreement under which Valeant
Pharma will acquire Medicis Pharma for $44.00 per share in cash.
The deal is expected to be worth approximately $2.6 billion.
On December 7, 2012, a special meeting will be held for Medicis
Pharma’s shareholders. The stockholders will vote on the
acquisition proposal. The deal is expected to close within four
business days following the satisfaction of all closing terms and
conditions. At the time of announcing the deal, Valeant Pharma
stated that the acquisition is expected to boost its earnings
immediately after the closure.
We note that Medicis Pharma is engaged in the development and
marketing of products for the treatment of dermatological and
aesthetic conditions in the US. Key products include Solodyn,
Perlane, Restylane, Ziana, Dysport and Zyclara. The impending
merger will broaden Valeant Pharma’s product portfolio
significantly and is expected to create a global leader in the
dermatological field.
We note that the dermatological segment has been in the spotlight
this year. Apart from Valeant Pharma’s impending acquisition of
Medicis Pharma, the acquisition of specialty dermatology generics
company, Fougera Pharma by Novartis (NVS) in July
2012, has also been in the news. Moreover, Allergan,
Inc. (AGN) recently announced that it has entered into an
agreement with a privately held company, SkinMedica, Inc. to
acquire the latter’s topical aesthetics skin care business.
Our Recommendation
We currently have an Outperform recommendation on Valeant Pharma.
The stock carries a Zacks #1 Rank (Strong Buy rating) in the short
run.
ALLERGAN INC (AGN): Free Stock Analysis Report
MEDICIS PHARM-A (MRX): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
VALEANT PHARMA (VRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Medicis (NYSE:MRX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Medicis (NYSE:MRX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Medicis Pharmaceutical Corp. (뉴욕 증권거래소)의 실시간 뉴스: 최근 기사 0
More Medicis News Articles